Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Inhibitors Of Virion Release

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

Inhibitors of Virion Maturation and Assembly

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...

Hepatitis

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...

Inhibitors of Bacterial DNA Synthesis

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Drug-Related Brain Vacuolation as an Unusual Presentation of Neurotoxicity in Sprague Dawley Rats.

International journal of toxicology·2026

Same author

Practical perspectives on addressing hepatotoxicity during clinical candidate selection.

Expert opinion on drug metabolism & toxicology·2025

Same author

<i>Medicinal Chemistry Reviews</i>, Volume 59.

ACS medicinal chemistry letters·2025

Same author

<i>Medicinal Chemistry Reviews</i>, Volume 59.

Journal of medicinal chemistry·2025

Same author

Exploring Integrin α5β1 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension: Insights From Comprehensive Multicenter Preclinical Studies.

Circulation·2025

Same author

Discovery of GS-2278, a Potent and Selective LPAR1 Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.

Journal of medicinal chemistry·2024

Search research articles

Related Experiment Video

Updated: Jun 11, 2026

A Protocol for Analyzing Hepatitis C Virus Replication

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

HCV NS5B polymerase inhibitors.

William J Watkins¹, Adrian S Ray, Lee S Chong

¹Gilead Sciences Inc, Foster City, CA 94404, USA. Will.watkins@gilead.com

Current Opinion in Drug Discovery & Development

|July 3, 2010

Summary

Researchers have developed nucleoside and non-nucleoside inhibitors targeting the Hepatitis C Virus (HCV) NS5B polymerase, with several agents progressing to clinical trials for improved treatment efficacy.

Area of Science:

Hepatology
Virology
Medicinal Chemistry

Background:

The Hepatitis C Virus (HCV) NS5B polymerase is a critical target for antiviral drug development.
Significant research has focused on identifying both nucleos(t)ide and non-nucleoside inhibitors.

Purpose of the Study:

To review the historical optimization of chemical series leading to clinical candidates for HCV NS5B polymerase inhibition.
To summarize recent advancements in the field, focusing on clinical efficacy and potential for combination therapies.

Main Methods:

Literature review of published studies and clinical trial data.
Analysis of chemical structures and structure-activity relationships of inhibitors.
Evaluation of clinical efficacy data for advanced drug candidates.

More Related Videos

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Related Experiment Videos

Last Updated: Jun 11, 2026

A Protocol for Analyzing Hepatitis C Virus Replication

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Main Results:

Several nucleos(t)ide and non-nucleoside inhibitors targeting HCV NS5B polymerase have been identified.
Promising agents have advanced into various stages of clinical development.
Recent developments highlight the efficacy of these inhibitors and their potential in combination studies.

Conclusions:

The development of HCV NS5B polymerase inhibitors has shown significant progress.
Optimized chemical series have yielded clinical candidates with demonstrated efficacy.
Future research should explore combination strategies for enhanced HCV treatment outcomes.